156 related articles for article (PubMed ID: 11698283)
1. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues.
Harig S; Witzens M; Krackhardt AM; Trojan A; Barrett P; Broderick R; Zauls AJ; Gribben JG
Blood; 2001 Nov; 98(10):2999-3005. PubMed ID: 11698283
[TBL] [Abstract][Full Text] [Related]
2. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity.
Gricks CS; Gribben JG
Curr Pharm Des; 2003; 9(23):1889-903. PubMed ID: 12871193
[TBL] [Abstract][Full Text] [Related]
4. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.
Zirlik KM; Zahrieh D; Neuberg D; Gribben JG
Blood; 2006 Dec; 108(12):3865-70. PubMed ID: 16902144
[TBL] [Abstract][Full Text] [Related]
6. Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.
Takaki T; Hiraki A; Uenaka A; Gomi S; Itoh K; Udono H; Shibuya A; Tsuji T; Sekiguchi S; Nakayama E
Int J Oncol; 1998 May; 12(5):1103-9. PubMed ID: 9538136
[TBL] [Abstract][Full Text] [Related]
7. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.
Trojan A; Witzens M; Schultze JL; Vonderheide RH; Harig S; Krackhardt AM; Stahel RA; Gribben JG
Cancer Res; 2001 Jun; 61(12):4761-5. PubMed ID: 11406549
[TBL] [Abstract][Full Text] [Related]
8. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution.
Bownds S; Tong-On P; Rosenberg SA; Parkhurst M
J Immunother; 2001; 24(1):1-9. PubMed ID: 11211143
[TBL] [Abstract][Full Text] [Related]
9. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
[TBL] [Abstract][Full Text] [Related]
10. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice.
Boesen A; Sundar K; Coico R
Clin Diagn Lab Immunol; 2005 Oct; 12(10):1223-30. PubMed ID: 16210487
[TBL] [Abstract][Full Text] [Related]
11. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
Bae J; Smith R; Daley J; Mimura N; Tai YT; Anderson KC; Munshi NC
Clin Cancer Res; 2012 Sep; 18(17):4850-60. PubMed ID: 22753586
[TBL] [Abstract][Full Text] [Related]
12. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide.
Tangri S; Ishioka GY; Huang X; Sidney J; Southwood S; Fikes J; Sette A
J Exp Med; 2001 Sep; 194(6):833-46. PubMed ID: 11560998
[TBL] [Abstract][Full Text] [Related]
13. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
14. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.
Hernandez J; Garcia-Pons F; Lone YC; Firat H; Schmidt JD; Langlade-Demoyen P; Zanetti M
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12275-80. PubMed ID: 12218171
[TBL] [Abstract][Full Text] [Related]
15. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.
Petersen TR; Buus S; Brunak S; Nissen MH; Sherman LA; Claesson MH
Scand J Immunol; 2001 Apr; 53(4):357-64. PubMed ID: 11285115
[TBL] [Abstract][Full Text] [Related]
16. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
Takahashi T; Irie RF; Nishinaka Y; Hoon DS
Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
[TBL] [Abstract][Full Text] [Related]
17. [Function analysis of the family-specific CTL induced by peptides derived from IgHV gene framework region of B-cell malignance].
Guo XL; Zhu P; Liu Y; Liu J; Zhu X
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):453-7. PubMed ID: 16383233
[TBL] [Abstract][Full Text] [Related]
18. A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.
Sun W; Shi J; Wu J; Zhang J; Chen H; Li Y; Liu S; Wu Y; Tian Z; Cao X; Li N
Cell Mol Immunol; 2018 Aug; 15(8):768-781. PubMed ID: 29375131
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma.
Bae J; Carrasco R; Lee AH; Prabhala R; Tai YT; Anderson KC; Munshi NC
Leukemia; 2011 Oct; 25(10):1610-9. PubMed ID: 21660045
[TBL] [Abstract][Full Text] [Related]
20. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
